Adalvo is strategically advancing in the development of Ceftazidime + Avibactam, a complex and differentiated antibiotic combination, aiming to be First To File in all major markets.
Based on the reference brand Zavicefta (EU)/ Avycaz (US), Ceftazidime + Avibactam is indicated in the treatment for complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), including pyelonephritis, and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).
With a total IQVIA MAT sale of $535 million in 2023 and a 3Y CAGR of 6%, Ceftazidime + Avibactam has demonstrated significant growth potential.
Adalvo is on track for a Day-1 launch in all major markets, thanks to a well defined product pathway. This demonstrates our commitment to efficiently meeting patients need for affordable medicine.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward
Partner up now!